For Chronic Leukemia Patients, the News Just Got Even Better
Several chronic lymphocytic leukemia (CLL) patients at the Wilmot Cancer Institute took part in two groundbreaking, nationwide phase 3 studies that are changing the way doctors treat the disease. The positive results are being reported this weekend at the 2018 American Society of Hematology (ASH) annual meeting — and will immediately impact CLL patients in the Rochester region and across the U.S., said Paul Barr, M.D., director of Wilmot’s Clinical Trials Office.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Hematology | Leukemia | Study | Universities & Medical Training